A crucial cautionary note on frequently incorrect dose equivalence between ketamine and esketamine.
Molecular Psychiatry August 3, 2026 DOI: 10.1038/s41380-026-03807-w (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Topics | Esketamine Ketamine |
| Key points | Argues that dose equivalence between ketamine and esketamine is frequently incorrect and cautions against assuming a simple conversion, as the compounds differ in potency and clinical use. |
Abstract
A crucial cautionary note on frequently incorrect dose equivalence between ketamine and esketamine.
Citations in the library
Cites 13
- NMDAR inhibition-independent antidepressant actions of ketamine metabolites Nature April 24, 2016
- Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation American Journal of Psychiatry March 17, 2021
- Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism American Journal of Psychiatry August 29, 2018
- Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study Biological Psychiatry November 4, 2015
- Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD) Molecular Psychiatry October 3, 2018
and 8 more in the library